Fortress Biotech, Inc. (NASDAQ:FBIO - Get Free Report) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.75 and traded as high as $1.96. Fortress Biotech shares last traded at $1.89, with a volume of 236,600 shares traded.
Fortress Biotech Stock Down 2.2%
The firm has a 50-day moving average price of $1.89 and a two-hundred day moving average price of $1.75. The firm has a market cap of $53.52 million, a price-to-earnings ratio of -0.81 and a beta of 1.76. The company has a debt-to-equity ratio of 1.74, a quick ratio of 1.55 and a current ratio of 1.72.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of FBIO. Nantahala Capital Management LLC grew its stake in shares of Fortress Biotech by 159.3% in the 1st quarter. Nantahala Capital Management LLC now owns 325,520 shares of the biopharmaceutical company's stock valued at $508,000 after purchasing an additional 200,000 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Fortress Biotech by 125.1% in the 4th quarter. Renaissance Technologies LLC now owns 175,800 shares of the biopharmaceutical company's stock valued at $356,000 after buying an additional 97,712 shares during the period. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Fortress Biotech by 8.7% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 1,004,365 shares of the biopharmaceutical company's stock valued at $1,567,000 after buying an additional 80,058 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of Fortress Biotech by 30.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 239,594 shares of the biopharmaceutical company's stock valued at $485,000 after buying an additional 55,648 shares during the period. Finally, Two Sigma Investments LP acquired a new stake in shares of Fortress Biotech in the 4th quarter valued at approximately $109,000. 96.51% of the stock is currently owned by hedge funds and other institutional investors.
About Fortress Biotech
(
Get Free Report)
Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.
Recommended Stories
Before you consider Fortress Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortress Biotech wasn't on the list.
While Fortress Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access